Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940952 | 0.95 | ALDH1A1 (0.54) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL29552446 | 0.90 | TSHR (0.58) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL19437142 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3223441 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL4379957 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3203924 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3219056 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL4386420 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3204209 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL1756904 | 0.89 | CPB1 (0.58) | ALDH1A1GAATSHRCPB1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-109153635-B | Neuropeptide S receptor (NPSR) agonists | 研究三角协会 | 2022-04-08 | — | — | CN | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-10927118-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-02-23 | — | — | US | disclosed |
| US-20200339564-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-24 | — | — | US | disclosed |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-06 | — | — | US | disclosed |
| WO-2017176461-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-10-12 | — | — | WO | disclosed |
| US-8871774-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130345218-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-2651941-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651940-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083121-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | ALDH1A1 3790/4885GAA 346/4885TSHR 3992/4885 |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | ALDH1A1 3790/4885GAA 346/4885TSHR 3992/4885 |
| US-10927118-B2 | Inhibitors of influenza virus replication and uses thereof | EIF2AK2, POLRMT, ZC3HAV1 | ALDH1A1 4038/4885GAA 464/4885TSHR 3985/4885 |
| US-20200339564-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | EIF2AK2, ZC3HAV1, MAVS | ALDH1A1 3638/4885GAA 486/4885TSHR 4068/4885 |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | ZC3HAV1, MAVS, POLRMT | ALDH1A1 3909/4885GAA 508/4885TSHR 4049/4885 |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | ALDH1A1 3087/4885GAA 500/4885TSHR 2296/4885 |
| US-20130345218-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | ALDH1A1 3087/4885GAA 500/4885TSHR 2296/4885 |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | ALDH1A1 4747/4885GAA 671/4885TSHR 62/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | ALDH1A1 3790/4885GAA 346/4885TSHR 3992/4885 |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | ALDH1A1 3087/4885GAA 500/4885TSHR 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.